

Fact Sheet RNA Research and Pilot Manufacturing Facility



Overview

The NSW Government is delivering a new RNA Research and Pilot Manufacturing Facility that will enable research, development and production of a broad spectrum of RNA technologies locally.

The New South Wales Government has committed \$96 million to build a Ribonucleic Acid (RNA) Research and Pilot Manufacturing Facility at Macquarie University's Wallumattagal Campus.

An additional \$119 million has been announced over 10 years for RNA research and development initiatives.

The new facility will be located in the Connect Innovation Precinct at Macquarie University and operated by Aurora Biosynthetics, part of a global therapeutics company.

Benefits

The project will:

- Be the first opportunity for RNA research and development to be tested and developed locally, across the broad spectrum of RNA technology, reducing Australia's reliance on international supply.
- Provide Australian patients with faster access to new and innovative RNA therapeutics to treat diseases such as cancer and rare genetic diseases.

- Attract global industry investment to Australia, foster local jobs and skills and secure domestic-market access to future therapeutics.
- Be central to NSW's thriving RNA research and development ecosystem, surrounded by medical and research facilities, existing infrastructure, and world-leading RNA and cell and gene therapy expertise.
- Boost innovation and technology in NSW, centralise RNA knowledge and expertise, create highly skilled jobs, and help NSW become a global leader in RNA research and production.
- Capitalise on NSW's competitive advantage by translating its strengths in research and development into a sustainable commercial pipeline of RNA therapeutics and products.

Fast Facts

Funding

\$96 million and an additional \$119 million for research and development

Project Sponsor

Office of the Chief Scientist and Engineer

Current status

Delivery

Location

Macquarie Park (Macquarie University)

Construction start

August 2024

Operator

Aurora Biosynthetics

Milestones

O Late 2021

Project announced

Late 2022

Site confirmed

Early 2023

Industry partner confirmed

Mid - Late 2023

Schematic designed completed

Early 2024

Main works contract awarded

Mid 2024

Construction commenced

O 2026

Construction and fit out completed

If you have any questions or would like more information please contact our project team.

Email: HI-RNA@health.nsw.gov.au.



For an interpreter, call 131 450 and ask them to call 02 9978 5956

For more information

T: 02 9978 5956

E: HI-RNA@health.nsw.gov.au **W**: hinfra.health.nsw.gov.au